Novem Group Acquires 7,788 Shares of Merck & Co., Inc. $MRK

Novem Group lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 16.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 56,016 shares of the company’s stock after buying an additional 7,788 shares during the period. Merck & Co., Inc. comprises 0.7% of Novem Group’s holdings, making the stock its 25th largest position. Novem Group’s holdings in Merck & Co., Inc. were worth $7,198,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of MRK. Kingdom Financial Group LLC. bought a new stake in Merck & Co., Inc. during the fourth quarter worth about $25,000. Abound Financial LLC acquired a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $26,000. Prosperity Bancshares Inc bought a new position in Merck & Co., Inc. in the fourth quarter valued at approximately $26,000. High Note Wealth LLC grew its stake in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth approximately $31,000. Institutional investors own 76.07% of the company’s stock.

Insider Transactions at Merck & Co., Inc.

In other news, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the transaction, the executive vice president directly owned 45,509 shares of the company’s stock, valued at $6,073,631.14. This represents a 63.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Richard R. Deluca sold 20,784 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the completion of the transaction, the executive vice president directly owned 134,703 shares in the company, valued at $17,569,312.29. The trade was a 13.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 228,238 shares of company stock valued at $29,977,783. Corporate insiders own 0.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Guggenheim upped their price objective on Merck & Co., Inc. from $145.00 to $146.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. Wells Fargo & Company boosted their target price on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 8th. Weiss Ratings lowered shares of Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday. Finally, CICC Research initiated coverage on shares of Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price target on the stock. Fifteen analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $135.50.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrade and higher valuations: Daiwa Securities upgraded MRK from “neutral” to “outperform” and set a $143 price target. Other analysts have raised fair-value estimates into the $140–$155 range, citing pipeline progress, business-development activity and late-stage therapies. Daiwa Securities upgrade
• Positive Sentiment: Business momentum remains supportive: MRK recently touched a record high, while Keytruda demand, oncology products, new launches and Animal Health helped drive quarterly revenue of $16.61 billion, above the $16.37 billion consensus estimate. The company also exceeded earnings expectations and reported 5.1% year-over-year revenue growth. Merck fair value and pipeline progress
• Positive Sentiment: Income and diversification appeal: Merck declared its regular $0.85 quarterly dividend, or $3.40 annualized, while potential expansion of ENFLONSIA for RSV prevention could broaden growth beyond oncology.
• Neutral Sentiment: Insider selling warrants monitoring: EVP Chirfi Guindo sold 10,000 shares for $1.35 million, following substantial sales by executives Jennifer Zachary and Richard Deluca. Each executive retained a meaningful stake, so the transactions may reflect personal financial decisions rather than a deteriorating outlook. Merck insider selling report
• Negative Sentiment: Keytruda concentration is a future risk: Patent expiration and increasing competition could pressure Merck’s largest growth driver. Investors will need evidence that the pipeline and newer products can offset eventual Keytruda sales declines. Keytruda growth outlook

Merck & Co., Inc. Price Performance

NYSE:MRK opened at $135.78 on Friday. Merck & Co., Inc. has a 12-month low of $77.58 and a 12-month high of $135.97. The firm has a market capitalization of $334.98 billion, a price-to-earnings ratio of 108.62, a P/E/G ratio of 5.85 and a beta of 0.19. The stock’s 50 day moving average price is $125.54 and its two-hundred day moving average price is $119.94. The company has a quick ratio of 1.06, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The firm’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the previous year, the company posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, analysts anticipate that Merck & Co., Inc. will post 2.77 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is 272.00%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.